Navigation Links
Robbins & Myers Schedules Second Quarter Fiscal 2008 Financial Results Conference Call
Date:3/11/2008

DAYTON, Ohio, March 11 /PRNewswire-FirstCall/ -- Robbins & Myers, Inc. (NYSE: RBN) announced today that it will be releasing its second quarter fiscal 2008 financial results for the period ended February 29, 2008, after market close on Wednesday, March 26, 2008. A live webcast of the conference call will be held at 2:00 p.m., EDT on Thursday, March 27, 2008 with Peter C. Wallace, President and Chief Executive Officer, and Christopher M. Hix, Vice President and Chief Financial Officer. They will discuss the Company's performance and respond to questions from the financial community.

Robbins & Myers invites interested investors to listen to the webcast, which will be broadcast live on its website http://www.robn.com. A webcast replay will be available at the website and a telephonic replay will be available beginning 4:00 p.m., EDT March 27, 2008, by dialing +1-888-286-8010 in the U.S. and entering conference ID # 30887500. For those outside the U.S., the international replay number is +1-617-801-6888 with the same ID number.

Robbins & Myers, Inc. is a leading supplier of highly-engineered, application-critical equipment and systems to energy, chemical, pharmaceutical and industrial markets.


'/>"/>
SOURCE Robbins & Myers, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Robbins & Myers to Present at Gabelli Conference
2. Robbins & Myers to Present at Merrill Lynch Growth Industrials Conference December 13, 2007
3. Robbins & Myers Presenting at Bear Stearns 3rd Annual Commodities and Capital Goods Conference November 28, 2007
4. Robbins Bros. Gives Water at AIDS Walk L.A.
5. Robbins & Myers Announces Regular Quarterly Cash Dividend
6. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
7. Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
8. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
9. Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors
10. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
11. American Cancer Society to Present Highest Honor to Matthew L. Myers, Douglas R. Lowy, and Mark Schiffman for Outstanding Contributions to Cancer Fight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... CA (PRWEB) , ... January 15, 2017 , ... ... their choice of best physicians in eight Bay Area counties for 2017. Almost ... the healthcare research company managing the award process. Results were announced the magazine’s ...
(Date:1/14/2017)... ... 2017 , ... Healthy living brand Moody Zook recently came ... With more and more people opting to go organic in their lifestyle, the ... to specific needs. , Moody Zook focused particularly on their newly launched activated ...
(Date:1/13/2017)... California (PRWEB) , ... January 13, 2017 , ... ... carbohydrates that raise blood sugar levels. Counting carbohydrates is as easy as checking ... the only nutrient that affects blood sugar levels. Despite being sugar-free, proteins can ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... taken on the challenge of providing additional organic alternatives for customers who have ... of the brand’s new line of all-natural activated charcoal products, Moody Zook Chief ...
(Date:1/13/2017)... PA (PRWEB) , ... January 13, 2017 , ... "We ... and attractive to wear," said one of two inventors from Virginia Beach, Va. , ... to normally mundane braces. , The accessories allow braces to be customized to ...
Breaking Medicine News(10 mins):
(Date:1/12/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing ... this week,s Orlando Dermatology Aesthetic & Clinical (ODAC) Conference, which ... inflammation. The data will be shared in a ... at ODAC, which is being held Jan. 13-16 in ... ...
(Date:1/12/2017)...   TyrNovo , s NT219 drug candidate ... cancer drug resistance and would be ... NT219 is a novel proprietary ... ( IRS1/2 and STAT3) highly involved in ... .   NT219 has demonstrated ...
(Date:1/12/2017)... -- "Global Lung Cancer Vaccine Market & Pipeline ... trends in the global lung cancer vaccine market. ... available in the market. This report analyzes the ... in clinical pipeline and gives comprehensive clinical insight ... the lung cancer vaccines. Currently there are 9 ...
Breaking Medicine Technology: